In a bid to replace its expired base shelf prospectus and corresponding shelf registration statement on form F-10, Aurinia Pharmaceuticals files new tentative base shelf prospectus with the securities commission in every province of Ontario, Alberta and British Columbia in Canada.
Once the prospectus becomes effective for duration of 25 months, up to US$250,000,000 of common shares, warrants, subscription receipts, debt securities will be allowed to be offered by Aurinia who does not intend to embark on right now but can access capital at its own discretion. The amount and timings of the offering will depend on the financial requirements and market situations. In addition to this the prospectus permits Aurinia to record a valid registration statement to certain holders of warrants issued under a private placement that happened in June 2016. Specific terms will be entailed in the prospectus. Unless it becomes effective the company will not be allowed to sell or solicit an offer to buy or sell any of these securities as it would be rendered unlawful.